NoBlood

FDA News:

Bayer Stops Worldwide Sales of Trasylol Pending Safety Data

Bayer is suspending global marketing of its clotting drug Trasylol as the FDA waits for additional data from a study that suggested the drug was associated with an increased risk of death.


The FDA requested the marketing suspension once it learned additional information from the study might not reach the agency for six weeks or longer, Office of New Drugs Director John Jenkins said. The FDA will gradually remove products from the marketplace to avoid shortages of the few alternative drugs used to limit blood loss during coronary artery bypass...(Continued)

__________________
Sharon Grant
Editorial Team